Taysha Gene Therapies Total Long-Term Assets 2020-2024 | TSHA

Taysha Gene Therapies total long-term assets from 2020 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Taysha Gene Therapies Annual Total Long-Term Assets
(Millions of US $)
2023 $23
2022 $30
2021 $54
2020 $1
2019 $
Taysha Gene Therapies Quarterly Total Long-Term Assets
(Millions of US $)
2024-06-30 $22
2024-03-31 $22
2023-12-31 $23
2023-09-30 $24
2023-06-30 $27
2023-03-31 $29
2022-12-31 $30
2022-09-30 $68
2022-06-30 $65
2022-03-31 $59
2021-12-31 $54
2021-09-30 $44
2021-06-30 $35
2021-03-31 $3
2020-12-31 $1
2020-09-30 $0
2020-06-30
2020-03-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.490B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00